Abstract:Knee osteoarthritis (KOA) is the most common joint inflammatory disease in orthopedics. The main feature is the gradual degeneration and loss of articular cartilage, accompanied by changes in joint structure and function. [ 1 ] After entering the 21st century, because of the increase in life expectancy and increase in body mass index due to the increase of population of old people, the prevalence of KOA has increased significantly and tended to be younger. [ 2 ] Currently, KOA accounts for 85% of the global burden of osteoarthritis, and the incidence of symptomatic KOA is 8.1%. [ 3 ] The main clinical manifestations of KOA are inconvenient movement of the limbs, difficulty in moving, and pain and swelling around the joints, which are more obvious after waking up in the morning, and can lead to paralysis in severe cases in the later stage. [ 2 ] Inflammation is the most common cause of joint pain and patient disability, and no effective treatment has been found to delay the progression of KOA, so most patients will undergo total joint replacement to relieve symptoms and improve physical performance, but it is expensive and traumatic large, slow recovery in the later period. [ 4–6 ] Therefore, it is crucial to understand the pathogenic process of KOA and the cellular and molecular mechanisms involved. The current process of osteoarthritis of the knee contains 2 basic aspects: the action of different joint elements and posttraumatic osteoarthritis formation. [ 7 , 8 ] On one hand, in nontraumatic circumstances, the development of knee osteoarthritis is a degenerative pathology associated with aging. Injuries to the components of the knee joint, such as synovitis, ligament, meniscus, free bodies, popliteal cysts, and chondromalacia of the patella, can also result in the development of knee osteoarthritis. In addition, knee osteoarthritis can be brought on by putting on too much weight, adopting bad gait patterns, squatting for extended periods of time, and exposing the knee joint to the cold. [ 4 , 9 ] On the other hand, posttraumatic osteoarthritis development, a progressive form of arthritis in the knee following trauma, is a significant contributor to osteoarthritis of the knee. It has clinical symptoms with osteoarthritis, but it also has a clear history of trauma, such as transarticular fractures. [ 10 , 11 ] At present, the most common manifestation of KOA is pain, and the effective drugs for pain relief are nonsteroidal antiinflammatory drugs. [ 12 ] However, such drugs are only suitable for short-term pain relief, and cannot control the wear and tear of articular cartilage, and cannot solve the fundamental problem. [ 13 ] Moreover, such drugs may cause gastrointestinal discomfort such as nausea and vomiting, and increase the risk of gastrointestinal bleeding. [ 14 ] Therefore, it is imperative to develop a drug that can maintain the curative effect of the drug and reduce side effects as much as possible.

Structure-Guided Discovery of Potent and Selective CLK2 Inhibitors for the Treatment of Knee Osteoarthritis

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype

Tetrandrine Inhibits the Wnt/β-Catenin Signalling Pathway and Alleviates Osteoarthritis: an in Vitro and in Vivo Study

Discovery of 4-Aminoquinoline-3-carboxamide Derivatives As Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis

Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases

Lead optimization of cathepsin K inhibitors for the treatment of Osteoarthritis

Quercetin Mediates TSC2-RHEB-mTOR Pathway to Regulate Chondrocytes Autophagy in Knee Osteoarthritis.

Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships

Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2

Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors

Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer

Molecular Classification of Knee Osteoarthritis

Small molecule inhibitors of osteoarthritis: Current development and future perspective

Exploration of Simiao-Yongan Decoction on knee osteoarthritis based on network pharmacology and molecular docking

Rational Modification, Synthesis and Biological Evaluation of 3,4-Dihydroquinoxalin-2(1h)-one Derivatives As Potent and Selective C-Jun N-terminal Kinase 3 (JNK3) Inhibitors.

SKP2-mediated ubiquitination and degradation of KLF11 promotes osteoarthritis via modulation of JMJD3/NOTCH1 pathway

Discovery of a novel cyclin-dependent kinase 8 inhibitor with an oxindole core for anti-inflammatory treatment

Icariin: A Potential Molecule for Treatment of Knee Osteoarthritis

Structure Based Design of N-(3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides As Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors.

Deapi-platycodin D3 attenuates osteoarthritis development via suppression of PTP1B